发布求助
文献互助 智能选刊 最新文献

Immuno-oncology technology最新文献

筛选
英文 中文
83P Immunomonitoring of dendritic cell-based vaccination post-metastasectomy in colorectal cancer: Preliminary findings from the phase II COREVAX-1 trial 结直肠癌转移切除术后树突状细胞免疫接种的免疫监测：来自II期COREVAX-1试验的初步发现
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101168
F.G. Sullo , J. Bulgarelli , D. Fanelli , C. Piccinini , A.M. Granato , E. Pancisi , M. Petrini , I. Azzali , G. Gentili , A. Passardi , L. Ridolfi , F. De Rosa
{"title":"83P Immunomonitoring of dendritic cell-based vaccination post-metastasectomy in colorectal cancer: Preliminary findings from the phase II COREVAX-1 trial","authors":"F.G. Sullo , J. Bulgarelli , D. Fanelli , C. Piccinini , A.M. Granato , E. Pancisi , M. Petrini , I. Azzali , G. Gentili , A. Passardi , L. Ridolfi , F. De Rosa","doi":"10.1016/j.iotech.2025.101168","DOIUrl":"10.1016/j.iotech.2025.101168","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101168"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
85P HPK1 inhibition enhances tumor-reactive TIL expansion from pMMR colorectal cancer liver metastases 85P HPK1抑制增强pMMR结直肠癌肝转移瘤反应性TIL扩增
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101170
L.P. del Carpio Huerta , A. Muñoz-Merino , M. Costa-García , J.A. Marin Jimenez , L. Lladó , E. Ramos , D. Garcia Molleví , A. Antolin , F. Losa , C. Santos Vivas , R. Alemany , J.M. Piulats , R. Salazar Soler
{"title":"85P HPK1 inhibition enhances tumor-reactive TIL expansion from pMMR colorectal cancer liver metastases","authors":"L.P. del Carpio Huerta , A. Muñoz-Merino , M. Costa-García , J.A. Marin Jimenez , L. Lladó , E. Ramos , D. Garcia Molleví , A. Antolin , F. Losa , C. Santos Vivas , R. Alemany , J.M. Piulats , R. Salazar Soler","doi":"10.1016/j.iotech.2025.101170","DOIUrl":"10.1016/j.iotech.2025.101170","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101170"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
103P Nonviral CRISPR/Cas-engineered tumor-infiltrating lymphocytes with inducible cytokine release and checkpoint resistance for adoptive T cell therapy 103P非病毒CRISPR/ cas工程肿瘤浸润淋巴细胞诱导细胞因子释放和检查点抵抗过继T细胞治疗
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101188
N.S. Mikkelsen , M.D.D. Crowther , R. Bak , I.M. Svane , Ö. Met
{"title":"103P Nonviral CRISPR/Cas-engineered tumor-infiltrating lymphocytes with inducible cytokine release and checkpoint resistance for adoptive T cell therapy","authors":"N.S. Mikkelsen , M.D.D. Crowther , R. Bak , I.M. Svane , Ö. Met","doi":"10.1016/j.iotech.2025.101188","DOIUrl":"10.1016/j.iotech.2025.101188","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101188"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
39P Dietary water intake correlates with therapeutic outcomes in advanced NSCLC treated with immune checkpoint inhibitors 饮食饮水与免疫检查点抑制剂治疗晚期非小细胞肺癌的治疗结果相关
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101122
J. Zhang , H. Xuan , T. McCorkle , Q. Dai , D. Sullivan , K. Lee , M. Phadnis , C. Zhong , C.H. Huang
{"title":"39P Dietary water intake correlates with therapeutic outcomes in advanced NSCLC treated with immune checkpoint inhibitors","authors":"J. Zhang , H. Xuan , T. McCorkle , Q. Dai , D. Sullivan , K. Lee , M. Phadnis , C. Zhong , C.H. Huang","doi":"10.1016/j.iotech.2025.101122","DOIUrl":"10.1016/j.iotech.2025.101122","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101122"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
46P Monitoring immunodynamics in a neoadjuvant chemo-immunotherapy protocol for triple negative breast cancer: Preliminary data from the TriBreCa study 三阴性乳腺癌新辅助化疗免疫治疗方案的免疫动力学监测：TriBreCa研究的初步数据
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101129
P. Rodrigues Santos , R.A. Santos , B. Darmits , A.R. Paiva , N. Castelo-Branco , T.V. Cunha Pereira , G.M. Sousa
{"title":"46P Monitoring immunodynamics in a neoadjuvant chemo-immunotherapy protocol for triple negative breast cancer: Preliminary data from the TriBreCa study","authors":"P. Rodrigues Santos , R.A. Santos , B. Darmits , A.R. Paiva , N. Castelo-Branco , T.V. Cunha Pereira , G.M. Sousa","doi":"10.1016/j.iotech.2025.101129","DOIUrl":"10.1016/j.iotech.2025.101129","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101129"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
24P Comprehensive genetic analysis reveals LRP1B mutations as prognostic factors associated with response to immunotherapy in non-small cell lung cancer patients 24P综合遗传分析显示LRP1B突变是影响非小细胞肺癌患者免疫治疗应答的预后因素
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101107
M. Canale , M. Urbini , D. Angeli , M. Tebaldi , E. Petracci , M. Pontillo , G. Marisi , R. Camara , C. Sbrighi , E. Chiadini , L. Capelli , F. Citarella , P. Cravero , A. Verlicchi , K. Andrikou , L. Crinò , A. Delmonte , N. Normanno , P. Ulivi
{"title":"24P Comprehensive genetic analysis reveals LRP1B mutations as prognostic factors associated with response to immunotherapy in non-small cell lung cancer patients","authors":"M. Canale , M. Urbini , D. Angeli , M. Tebaldi , E. Petracci , M. Pontillo , G. Marisi , R. Camara , C. Sbrighi , E. Chiadini , L. Capelli , F. Citarella , P. Cravero , A. Verlicchi , K. Andrikou , L. Crinò , A. Delmonte , N. Normanno , P. Ulivi","doi":"10.1016/j.iotech.2025.101107","DOIUrl":"10.1016/j.iotech.2025.101107","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101107"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Title page 标题页
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/S2590-0188(25)00504-0
{"title":"Title page","authors":"","doi":"10.1016/S2590-0188(25)00504-0","DOIUrl":"10.1016/S2590-0188(25)00504-0","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101544"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
54P NLR/PLR + TILs as potential biomarkers in early TNBC patients receiving neo-adjuvant chemo-immunotherapy 54P NLR/PLR + TILs作为早期TNBC患者接受新辅助化疗免疫治疗的潜在生物标志物
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/j.iotech.2025.101137
K. Yazdanpanah Ardakani , S. Capici , F.F. Pepe , C. Dibella , K. Mohammadi , G. Passarella , M.E. Cazzaniga
{"title":"54P NLR/PLR + TILs as potential biomarkers in early TNBC patients receiving neo-adjuvant chemo-immunotherapy","authors":"K. Yazdanpanah Ardakani , S. Capici , F.F. Pepe , C. Dibella , K. Mohammadi , G. Passarella , M.E. Cazzaniga","doi":"10.1016/j.iotech.2025.101137","DOIUrl":"10.1016/j.iotech.2025.101137","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101137"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145836560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial nivolumab加低分割放疗治疗转移性粘膜黑色素瘤的II期临床试验：PORTER-M3试验
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-11-21 DOI: 10.1016/j.iotech.2025.101550
M. Nomura , M. Yoshimura , T. Yokota , S. Boku , I. Oze , H. Ishikawa , M. Muto
{"title":"Phase II trial on nivolumab plus hypofractionated radiotherapy in patients with metastatic mucosal melanoma: PORTER-M3 trial","authors":"M. Nomura ,&nbsp;M. Yoshimura ,&nbsp;T. Yokota ,&nbsp;S. Boku ,&nbsp;I. Oze ,&nbsp;H. Ishikawa ,&nbsp;M. Muto","doi":"10.1016/j.iotech.2025.101550","DOIUrl":"10.1016/j.iotech.2025.101550","url":null,"abstract":"<div><h3>Background</h3><div>The response rate of nivolumab monotherapy for mucosal melanoma is only ∼20%. The objective of this phase II trial was to evaluate the efficacy and safety of nivolumab in combination with radiotherapy for metastatic mucosal melanoma.</div></div><div><h3>Patients and methods</h3><div>The eligibility criteria were: histological diagnosis of metastatic mucosal melanoma, Eastern Cooperative Oncology Group performance status of 0 or 1, and presence of measurable lesions. Patients received nivolumab with concurrent radiotherapy for measurable lesions, for a total dose of 25 Gy in five fractions per week. The primary endpoint was the response rate of all lesions (overall response rate, ORR). The study was considered to have met its primary endpoint if at least 6 of the 17 patients had a response (ORR ≥35.3%). The secondary endpoints were the disease control rate, progression-free survival, overall survival, and toxicity.</div></div><div><h3>Results</h3><div>Eighteen patients were enrolled, and 17 were evaluable for efficacy. The ORR was 41.2%, with two patients showing complete response, five partial response, and four stable disease. The median progression-free and overall survival were 4.9 months [95% confidence interval (CI) 2.2-15.1 months] and 20.1 months (95% CI 7.5-31.5 months), respectively. Immune-related adverse events of grades 3 or 4 occurred in 35.2% (6/17) of the patients. The radiation-related adverse events were grade 3 radiation dermatitis in one patient and grade 3 radiation pneumonitis in one patient.</div></div><div><h3>Conclusions</h3><div>Concurrent radioimmunotherapy consisting of nivolumab and radiotherapy showed promising efficacy with a manageable safety profile in patients with metastatic mucosal melanoma, warranting further evaluation in large studies.</div></div>","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101550"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145748241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ESMO Immuno-Oncology Congress 2025 Officers ESMO免疫肿瘤学大会2025官员
Immuno-oncology technology Pub Date : 2025-12-01 Epub Date: 2025-12-26 DOI: 10.1016/S2590-0188(25)00508-8
{"title":"ESMO Immuno-Oncology Congress 2025 Officers","authors":"","doi":"10.1016/S2590-0188(25)00508-8","DOIUrl":"10.1016/S2590-0188(25)00508-8","url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"28 ","pages":"Article 101548"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145839444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书